Alphatec Holdings, Inc. (NASDAQ:ATEC) is a company that specializes in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. According to Bloomberg.com, the stock has received an average rating of “Buy” from seven research firms that currently cover the stock.
This positive rating is indicative of the confidence that analysts have in Alphatec Holdings’ potential for growth and success. Seven equities research analysts have specifically rated the stock as a buy. Additionally, these analysts have issued an average 12-month price objective of $22.00 for Alphatec Holdings.
As of August 17, 2023, ATEC opened at $14.39 on Thursday. Over the past twelve months, the stock’s lowest point was recorded at $7.11 while its highest point reached $19.14. With a market capitalization of $1.73 billion, Alphatec Holdings holds significant value within its sector.
From a financial perspective, Alphatec Holdings has a price-to-earnings (PE) ratio of -9.53 and a beta of 1.28. These figures provide insights into the company’s valuation relative to its earnings and its volatility compared to the overall market.
In terms of short-term trends, Alphatec Holdings’ 50-day moving average stands at $16.80 while its 200-day moving average is recorded at $15.64.
The core focus of Alphatec Holdings revolves around providing medical professionals with innovative spinal fusion technology products and solutions to address various spinal disorders effectively. This includes intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and biologics offerings.
Overall, with favorable ratings from multiple research firms and a solid product line aimed at treating spinal disorders, Alphatec Holdings appears well-positioned for growth in the future. Investors may find the company’s stock to be an attractive investment option based on the positive reports and analysts’ projections.
It is essential for prospective investors to conduct thorough research and analysis before making any financial decisions. As with any investment, there are inherent risks, and it is advisable to consult with a financial advisor or professional before making any investments. However, based on the current information available, Alphatec Holdings demonstrates promise as a potential investment within the spinal fusion technology sector.
Analyst Reports Provide Insights into Alphatec Holdings’ Stock Performance and Future Potential in the Medical Technology Industry
Alphatec Holdings, Inc. has recently received multiple reports from research analysts regarding its stock performance and ratings. The reports provide insights into the company’s potential growth and future prospects in the medical technology industry.
One research note from Needham & Company LLC revealed that they have increased their price target on Alphatec shares from $19.00 to $20.00, while also giving the stock a “buy” rating. This indicates that the analysts believe the company’s stock is undervalued and has potential for growth in the market.
HC Wainwright, another research firm, reiterated their “buy” rating on Alphatec shares and set a price target of $20.00 as well, aligning with Needham & Company’s evaluation of the stock’s value.
In contrast, StockNews.com provided a more skeptical viewpoint by initiating coverage on Alphatec with a “sell” rating. This suggests that StockNews.com believes the stock may not perform well in the market based on their analysis of the company and its industry.
Canaccord Genuity Group took a more positive stance by increasing their price target on Alphatec from $17.00 to $22.00, while also giving it a “buy” rating. This signifies their confidence in the company’s growth potential and indicates that they consider it an attractive investment opportunity within the medical technology sector.
Morgan Stanley expressed similar optimism by raising their price target from $19.00 to $23.00 and assigning an “overweight” rating to Alphatec shares. Their analysis suggests that Alphatec is poised for significant growth and outperformance compared to its competitors in the coming months.
Alphatec Holdings specializes in designing, developing, and marketing spinal fusion technology products and solutions for treating spinal disorders. Their product line includes intra-operative information systems, neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings. These products aim to improve the treatment options available for patients with spinal disorders.
In other news related to Alphatec Holdings, major shareholder Jennifer N. Pritzker purchased 2,400 shares of the company’s stock on August 10th. The transaction was valued at $35,976.00 with an average share price of $14.99. This acquisition indicates Pritzker’s confidence in the company’s future prospects and potential for growth.
Additionally, Director Paul Segal sold 71,329 shares of Alphatec stock on June 12th at an average price of $15.15 per share, totaling $1,080,634.35. The sale was disclosed in a filing with the Securities & Exchange Commission (SEC), which is available for public access.
It is worth noting that insiders within Alphatec have sold a significant number of shares recently as well. In total, they have sold approximately 142,721 shares of company stock worth $2,246,737 in the last quarter. Currently, insiders own 29.12% of the company’s stock.
Several institutional investors and hedge funds have also shown interest in Alphatec Holdings by buying and selling its shares recently. Notably, Nuveen Asset Management LLC increased its holdings by 12.1% during the second quarter to reach a total of 1,557,115 shares valued at $27,997,000. Castleark Management LLC saw a substantial increase in their stake by 62.3%, totaling 380,590 shares worth $6,843,000.
Wells Fargo & Company MN also boosted its holdings by acquiring an additional 12,964 shares during the same period and raising its stake by 37.2%. Moreover, Walleye Capital LLC and Walleye Trading LLC both increased their stakes in Alphatec by 10.5% and 43.2%, respectively.
Overall, these recent developments indicate a mix of positive and negative sentiment towards Alphatec Holdings. The company’s performance in the medical technology industry, as well as its stock value, will continue to be closely monitored by analysts and investors alike.